1/753
Looks like no tags are added yet.
glaucoma
group of ocular disorders characterized by changes in optic disk and loss of visual sensitivity and field
intraocular pressure is not part of current diagnostic criteria
glaucoma common in who
second cause of blindness
increases with age
more common in blacks
cause of glaucoma
build up of fluid (aqueous humor) in eye
increase pressure of anterior chamber
aqueous humor exits out of where
ciliary to anterior chamber
conventional route of aqueous humor removal
trabecular outflow
80-85%
nonconventional rout of aqueous humor removal
uveoscleral outflow
15-20
drugs to increase outflow of aqueous humor removal
should target conventional and non conventional
drugs should not target the same thing
most drugs target conventional
risk factors of glaucoma
IOP > 30 mmHg
suspicious optic disk fittings
FH
systemic vascular disease
increased age
asymmetric cups
high myopia
optic disk hemorrhages
increasing IOP over time or Increase/decrease of IOP
retinal nerve fiber defects
TII DM
african american or hispanic
optic disc cupping in glaucoma
an enlargement/deepening of the normal depression in the center of the optic disc due to loss of retinal ganglion cell axons.
risk factor of glaucoma
range of cupping
normal → mild → severe
asymmetric cupping
one eye has more cupping than another
open angle glaucoma
is a gradual, usually painless loss of peripheral vision caused by impaired aqueous humor drainage, increased intraocular pressure, and progressive optic nerve damage.
closed angle glaucoma
occurs when the iris blocks the drainage angle, causing a rapid increase in intraocular pressure that can lead to severe eye pain, headache, blurred vision, halos, nausea/vomiting, and optic nerve damage.
low risk medications for open angle glaucoma
systemic anticholinergics
heterocyclic antidepressants
phenothiazines
vasodilators
cimetidine
low risk medications for closed angle glaucoma
antihistamines
systemic anticholinergics
heterocyclic antidepsressents
phenothiazines
ipratropium
benzodiazepines
high risk medications for open angle glaucoma
corticosteroids
topical anticholinergics
high risk medications for closed angle glaucoma
topical anticholinergics
topical sympathomimetics
main drugs that risk glaucoma
antihistamines and anticholinergics
goals of therapy for glaucoma
lower IOP to a level associated with a decreased risk of optic nerve damage
approximately 25-30% - depends on situation tho
therapeutic approach starting with how many eyes
start in one eye to see if it works or if there are adverse effects
start in both eyes if very high IOP or advanced field loss
therapeutic approach drug concentrations
start with low concentrations of a single agent
when two eye drops are being used how is that done
instillation should be separated by at lease 3-5 minutes, ideally 10, because the eye can only hold one drop at a time
therapeutic approach monitoring
monitors for 2-4 weeks then every 3-4 months once IOP reaches an acceptable range
nasolacrimal occulsion
blockage of the nasolacrimal duct, preventing tears from draining from the eye into the nose and causing excessive tearing (epiphora).
how should the eye drops be administered
with nasolacrimal occlusion to improve absorption and bioavailbility
what kind of medicine is used in the start of glaucoma
beta blocker or prostaglandin analogue
alternative first line agent if contraindications to first line agent
brimonidine
after the start of therapy how long do you wait to asses
2-4 weeks
if there is an inadequate response to the first medicine what do you do
ensure compliance/administration technique
increase concentration if possible or increase frequency
switch to an alternative first line agent if no response or add a second first line agent if partial response
if there is intolerance to the first line response what do you
reduce the concentration if possible or
change the formulations or
switch to an alternative class or
switch to an alternative combination
after adjustment of drugs how long do you wait to assess
2-4 weeks
if there is a second inadequate response what do you do
ensure compliance
if no response try an alternative first line topical agent
if partial response add a second or third first line agent or topical CAI
if there is an intolerance after the first change of drugs what do you do
reduce the concentration if possible or
change the formulations or
switch to an alternative class or
switch to an alternative combination
after changing the drugs the second time how long do you wait before assessing
2-4 weeks
if there is another inadequate response (3rd) what do you do
ensure compliance
consider adding direct acting cholinergic agent or cholinesterase inhibitor
consider adding oral CAI in place of topical CAI
if there is another intolerance (3rd) what do you do
reduce the concentration if possible or
change the formulations or
switch to an alternative class or
switch to an alternative combination
after waiting another 2-4 weeks what do you do
if intolerance or inadequate response to maximally tolerated combination drug therapy persists consult to laser or surgical
therapeutic options for glaucoma
topical beta blockers
prostaglandin analogues
alpha andrenergic inhibitors
carbonic anhydrase inhibitors
topical parasympathomimetic agents - direct cholinergic agonist
cholinesterase inhibitors
topical beta blocker MOA
reduce IOP by decreasing the production of aqueous humor by the ciliary body without affecting aqueous humor outflow
topical beta blockers reduce IOP by what
20-25%
topical beta blocker local ADE
stinging
dry eyes
corneal anesthesia
blepharitis
blurred vision
conjunctivitis
uveitis
keratitis
stinging ADE from beta blockers is found in use of what drugs
betaxolol and metipranolol
system ADE of topical beta blockers
drugs may be absorbed and produce system effects
bradycardia
hypotension
bronchospasm
blocking symptoms of hypoglycemia
CNS effects
bronchospasms are seen with what topical beta blocker
non-selective beta blockers
what part of the eye do topical beta blockers act on
ciliary to produce less aqueous humor
kinds of beta blockers
betaxolol
carteolol
levobunolol
metipranolol
timolol
betaxolol is what kind of gluacoma drug
topical beta blocker
carteolol is what kind of gluacoma drug
topical beta blocker
levobunolol is what kind of gluacoma drug
topical beta blocker
metipranolol is what kind of gluacoma drug
topical beta blocker
timolol is what kind of gluacoma drug
topical beta blocker
when are topical beta blockers used
start of therapy
preferred first drug used
prostaglandin analogues MOA
increasing uveoscleral outflow (non-conventional route) of aqueous humor
analogue
a compound with a structure similar to another compound differing in specific atoms, functional groups, or substructures
prostaglandin analogues reduce IOP by what
25-35%
prostaglandin analogues are effective in what concentrations
low concentrations
prostaglandin analogues used in combination or not
may be used in combination
prostaglandin analogues ADEs
increased frequency of punctate corneal erosions
increased frequency of conjunctival hyperemia
iris hyperpigmentation
increased eyelash growth
what eye structure do prostaglandin analogues effect
uveoscleral outflow
prostaglandin analogues drugs
iatanoprost
bimatoprost
travoprost
latanoprost is what kind of glaucoma drug
prostaglandin analogue
bimatoprost is what kind of glaucoma drug
prostaglandin analogue
travoprost is what kind of glaucoma drug
prostaglandin analogue
when are prostaglandin analogues used in the glaucoma treatment algorithm
at the start of therapy or after assessment
alpha adrenergic agonist MOA
decrease ciliary body production of aqueous humor or increase in uveoscleral aqueous humor outflow
alpha adrenergic agonist reduces IOP by what
20-25%
how to use alpha adrenergic agonist with beta blockers
should be separated by more than 3 hours
alpha adrenergic agonists local ADEs
tearing
burning
ocular discomfort
browache
conjunctival hyperemia
blurred vision
discoloration of soft contact lenses
mydriasis
deposition of adrenochrome pigment in conjunctiva or cornea
alpha adrenergic agonist systemic ADEs
headache
faintness
hypotension
tachycardia
arrhythmias
tremor
pallor
alpha adrenergic agonist work on what part of the eye
ciliary body
kinds of alpha adrenergic agonists
epinephrine HCl
epinephrine bitartrate
dipivefrin
aparaclonidine
brimonidine
brimonidine/timolol
epinephrine HCl is what kind of glaucoma drug
alpha adrenergic agonist
epinephrine bitartrate is what kind of glaucoma drug
alpha adrenergic agonist
dipivefrin is what kind of glaucoma drug
alpha adrenergic agonist
apraclonidine is what kind of glaucoma drug
alpha adrenergic agonist
brimonidine is what kind of glaucoma drug
alpha adrenergic agonist
brimonidine/timolol is what kind of glaucoma drug
alpha adrenergic agonist and beta blocker combo
when are alpha adrenergic agonist used in the glaucoma treatment algorithm
alternative first line agent
or after the first assessment for inadequate response
carbonic anhydrase inhibitors MOA
decreases IOP by decreasing ciliary body aqueous humor secretion by 40-60%
active secretion of sodium and bicarbonate may produce an osmotic gradient resulting in transfer of water from the ciliary body to aqueous humor
carbonic anhydrase inhibitors reduce IOP by what
15-20% - topical
20-30% - oral products
carbonic anhydrase inhibitors in combination
may provide additive effect with beta blockers and cholinergic agents
when should carbonic anhydrase inhibitors be avoided
with sulfa allergy because it contains sulfonamide moieties
when are oral carbonic anhydrase inhibitors used
in patients failing to respond to or tolerate maximum topical therapy
carbonic anhydrase inhibitors local ADE
frequent transient burning or stinging
ocular discomfort
blurred vision
tearing
conjuctivitis
photophobia
carbonic anhydrase inhibitors systemic ADE
malaise
fatigue
anorexia
nausea
weight loss
altered taste
depression
decreased libido
carbonic anhydrase inhibitors acts on what eye part
ciliary
carbonic anhydrase inhibitors topical drugs
dorzolamide
brinzolamide
dorzolamide/timolol
brinzolamide/brimonidine
dorzolamide is what kind of gluacoma drug
topical carbonic anhydrase inhibitors
brinzolamide is what kind of gluacoma drug
topical carbonic anhydrase inhibitors
dorzolamide/timolol is what kind of gluacoma drug
topical carbonic anhydrase inhibitors
brinzolamide/brimonidine is what kind of gluacoma drug
topical carbonic anhydrase inhibitors
oral/IV carbonic anhydrase inhibitors drugs
acetazolamide
dichlorphenamide
methazolamide
acetazolamdie is what kind glaucoma drug
oral/IV carbonic anhydrase inhibitors drugs
dichlorphenamide is what kind glaucoma drug
oral carbonic anhydrase inhibitors drugs
methazolamide is what kind glaucoma drug
oral carbonic anhydrase inhibitors drugs
when is carbonic anhydrase inhibitors drugs used in glaucoma treatment algorithm
alternative first line agent when contraindication to a regular first line agent
topical parasympathomimetic agents MOA
reduce IOP by increasing aqueous humor trabecular outflow by opening the trabecular meshwork secondary to ciliary muscle contraction
topical parasympathomimetic agents reduce IOP how much
20-25%
topical parasympathomimetic agents and beta blockers
topical parasympathomimetic agents may enhance the effect of beta blockers
topical parasympathomimetic agents local ADE
miosis - decrease night vision
accommodative spasm
frontal headache
peri-orbital pain
eyelid twitching
conjunctival irritation